ERBB2 and breast carcinoma: Lapatinib is the first dual inhibitor of EGFR and ERBB2/HER2 for treating ERBB2-positive breast cancer, whereas brigatinib is a mixed inhibitor of ALK and EGFR used for the treatment of metastatic NSCLC.